Handbook of process chromatography: Development, manufacturing, validation and economics

Handbook of Process Chromatography: Development, Manufacturing, Validation and Economics

Volumn , Issue , 2007, Pages 1-363

  Hagel, Lars ^a   Jagschies, Günter ^a   Sofer, Gail ^b  

^a BIACORE AB   (Sweden)

^b GE HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85134419799     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (334)

1. Turner B.G. Approaches to achieving 5 g/L antibody titers through process development. presented at Bioprocess International Conference November 2006.
2. Wurm F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 2004, 22(11):1393-1398.
3. Kjeldsen T. Yeast secretory expression of insulin precursors. Appl. Microbiol. Biotechnol. 2000, 54:277-286.
4. Bezy P. Efficient pilot plant utilization, late stage research through post-approval. presented at Bioprocess International Conference May 2005.
5. Kamarck M.E. Building biomanufacturing capacity-the chapter and the verse. Nat. Biotechnol. 2006, 24(5):503-505.
6. Kretzmer G. Industrial processes with animal cells. Appl. Microbiol. Biotechnol. 2002, 59:135-142.
7. Kelley B. Very large scale monoclonal antibody purification: The case for conventional unit operations. Biotech. Progr. 2007, in press.
8. Lindsten J. August Krogh and the Nobel Prize to Banting and Macleod http://nobelprize.org/nobel_prizes/medicine/articles/lindsten/index.html.
9. Cohn E.J. The history of plasma fractionation. Adv. Mil. Med. 1948, 1:364-443.
10. Curling J.M. Methods of Plasma Protein Fractionation 1980, Academic Press, New York, N.Y. J.M. Curling (Ed.).
11. Pavlou A.K., Reichert J.M. Recombinant protein therapeutics-success rates, market trends and values to 2010. Nat. Biotechnol. 2004, 22(12):1513-1519.
12. Miyake T., Kung C.K.H., Goldwasser E. Purification of human erythropoietin. J. Biol. Chem. 1977, 252:5558-5564.
13. Fisher J.W. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. 2003, 228:1-14.
14. Walsh G. Biopharmaceuticals: recent approvals and likely directions. Trends Biotechnol. 2005, 23(11):553-558.
15. Biotechnology Medicines Survey 2004 Pharmaceutical Research and Manufacturing Association. http://www.phnna.org/new_medicines_in_development_for_biotechnology/.
16. Rader R.A. Biopharmaceutical Products in the U.S. and European Markets July 2005, 1015. BioPlan Associates, Rockville, MD. 4th edn.
17. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 2003, 22(2):151-185.
18. Ashton G. Growing pains for biopharmaceuticals. Nat. Biotechnol. 2001, 19:307-311.
19. Outlook 2005, Tufts Center for the Study of Drug Development January 2005.
20. J.M. Reichert, New biotechnology therapeutics, challenges for the industry, presented in June 12, 2004 at the 1st International Greek Biotechnology Forum.
21. Burrill G.S. Biotech 2006, Life sciences: a changing prescription. presented at BIO 2006 April 2006.
22. Challenge and Opportunity on the Critical Path to New Medical Products March 2004, US Department of Health and Human Services, FDA.
23. Outlook 2006, Tufts Center for the Study of Drug Development January 2006.
24. B.E.S.Langer, A survey of industry capacity. In Advances in Large Scale Biopharmaceutical Manufacturing and Scale-up Production, Vol. 2, E.S. Langer (ed), BioPlan Associates, Rockville, MD, pp. 707-727.
25. Kamarck M.E. Nat. Biotechnol. 2006, 24(5):503-505.
26. BAA 06-31, Accelerated Manufacturing of Pharmaceuticals (AMP), published by US Government Federal Business Opportunities Defense Advanced Research Projects Agency (DARPA). http://www.fbo.gov/spg/ODA/DARPA/CMO/BAA06-31/Attachments.html.
27. Pharma 2010, The Threshold of Innovation 2004, IBM Global Business Services, Somers, NY.
28. Guidance for Industry, PAT-A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance September 2004, FDA.
29. Genentech and Wyeth Announce Manufacturing Agreement http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home/news/pressreleases/2004/1145623187764.html.
30. Levine H.L. Assessing strategic options for biologies manufacturing. presented at IBC Bioprocess International Conference October 2004.
31. Coffman J., Bastek P., Brown P., Kramarczyk J., Sun Sh., Vunnum S., Dinn J., Kelley B. High-throughput screening of resins and excipients for downstream process development. presented at IBC Bioprocess International Conference October 2004.
32. Kelley B., Switzer M., Booth J., Coffman J. Application of high throughput screening to a Mab purification platform. presented at IBC Bioprocess International Conference September 2005.
33. Nachtmann F. Single-use disposables, benefits and limitations in process development and manufacturing. presented at IBC BioProcess International Conference April 2005.
34. Sinclair A., Monge M. Biomanufacturing for the 21st century, BioProcess International www.biopharmservices.com/Download/BPSCoG-Overview.pdf.
35. Bezy P. Efficient pilot plant utilization. presented at IBC BioProcess International Conference April 2005.
36. Smith M.P. Strategies for the purification of high titre, high volume mammalian cell culture batches. presented at IBC BioProcess International Conference April 2005.
37. Slaff G. Application of technology platforms to the purification of monoclonal antibodies. presented at IBC International Conference, Berlin April 2005.
38. Kelley B. Designing a 10-ton Mab process: is conventional chromatography limiting?. presented at American Chemical Society, Annual Conference, BIOT Division September 2006.
39. Adamson B. A new era in biotechnology. presented at IBC Bioproduction 2006, Dublin, Eire September 2006.
40. ICH Harmonized Tripartite Guideline Quality of biotechnological products: analysis of expression construct in cells used for production of r-DNA derived protein products ICH Q5B, available from the ICH homepage at. http://www.ich.org/cache/compo/276-254-l.html.
41. Walsh G. Biopharmaceuticals: recent approvals and likely directions. Trends Biotechnol. 2005, 23(11):553-558.
42. Turner B.G. Approaches to achieving 5 g/L antibody titers through process development, presented at Bioprocess International Conference, San Francisco November 2006.
43. Wurm F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 2004, 22(11):1393-1398.
44. Nichols W.W., Lardenoije R., Ledwith B.J., Brouwer K., Manam S., Vogels R., Kaslow D., Zuijdgeest D., Bett A.J., Chen L., Kaaden M.v.d., Galloway S.M., Hill R.B., Machotka S.V.C.AA., Lewis J., Martinez D., Lebron J., Russo C., Valerio D., Bout A. Propagation of adenoviral vectors: Use of PER.C6 cells in adenoviral vectors for gene therapy 2002, 129-166. Academic Press, New York. D.T. Curiel, J.T. Douglas (Eds.).
45. Coco-Martin J.M. Mammalian expression of therapeutic proteins: a review of advancing technology. BioProcess Int. 2004, 2(10):32-40.
46. Ventura S., Villaverde A. Protein quality in bacterial inclusion bodies. Trends Biotechnol. 2006, 24(4):179-185.
47. Wang C., Wang L., Geng X. Refolding recombinant human granulocyte colony stimulating factor expressed in E. coli. BioProcess Int. 2006, 4(5):48-54.
48. Manosroi J., Tayapiwatana C., Manosroi A., Beer J., Bergemann K., Werner R.G. Lekteplase- secreted tissue plasminogen activator derivative from Escherichia coli. Arzneimittelforschung 2002, 52:60-66.
49. Kawasaki T. Biopharma in Japan. Pharma Focus Asia 2006, 1:29-34.
50. Werner R.G. The development and production of biopharmaceuticals: technological and economic success factors. BioProcess Int. 2005, 3(9):6-15.
51. Li H., Sethuraman N., Stadheim T.A., Zha D., Prinz B., Ballew N., Bobrowicz P., Choi B.-K., Cook W.J., Cukan M., Houston-Cummings N.R., Davidson R., Gong B., Hamilton S.R., Hoopes J.P., Jiang Y., Kim N., Mansfield R., Nett J.H., Rios S., Strawbridge R., Wildt S., Gerngross T.U. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. Biotechnol. 2006, 24(2):210-215.
52. Nevalainen K.M.H., Valentino S.J.T., Berquist P.L. Heterologous protein expression in filamentous fungi. Trends Biotechnol. 2005, 23(9):468-474.
53. Dinnis D.M., James D.C. Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature?. Biotechnol. Bioeng. 2005, 91(2):180-189.
54. Bakker H., Bardor M., Molthoff J.W., Gomord V., Elbers I., Stevens L.H., Jordi W., Lommen A., Faye L., Lerouge P., Bosch D. Galactose-extended glycans of antibodies produced by transgenic plants. Proc. Natl. Acad. Sci. 2001, 98(5):2899-2904.
55. Gomord V., Chamberlain P., Jefferis R., Faye L. Biopharmaceutical production in plants: problems, solutions and opportunities. Trends Biotechnol. 2005, 23(11):559-565.
56. Vain P. Global trends in plant transgenic science and technology (1973-2003). Trends Biotechnol. 2006, 24(5):206-211.
57. Berberich S.A., Devine R.A. US regulation of plant-made biopharmaceuticals, part 1. BioPharm. Int. 2005, 18(1):38-47.
58. Dyck M.K., Lacroix D., Pothier F., Sirard M.-A. Making recombinant proteins in animals-different systems, different applications. Trends Biotechnol. 2003, 21(9):394-399.
59. Abola E.E., Bernstein E.C., Bryant S.H., Koetzle T.F., Weng J. Protein Data Bank. Crystallographic Databases-Information Content, Software Systems, Scientific Applications 1987, 107-132. Data Commission of the International Union of Crystallography, Bonn. F.H. Allen, G. Bergerhoff, R. Sievers (Eds.).
60. Bernstein E.C., Koetzle T.F., Williams G.J.B., Meyer E.F., Brice M.D., Rodgers J.R., Kennard O., Shimanouchi T., Tasumi M. The protein data bank: a computer-based archival file for macromolecular structures. J. Mol. Biol. 1977, 112:535-542.
61. ISO 14971: A Worldwide Risk Management Standard Available at. http://www.ich.org/LOB/media/MEDIA1957.pdf.
62. ICH Q9: Quality Risk Management Available at. www.ich.org.
63. Pharmaceutical cGMPs for the 21st Century: a risk-based approach Department of Health and Human Services, U.S. FDA. http://www.fda.gov/cder/gmp/gmp2004/GMP_finalreport2004.htm.
64. Seely R.J., Haury J. Applications of failure modes and effects analysis to biotechnology manufacturing processes. Process Validation in Manufacturing of Biopharmaceuticals 2005, CRC Press, Boca Raton, FL. A.S. Rathore, G. Sofer (Eds.).
65. Kradjian S. Regulatory risk assessment in early development. RA Focus March 2006, 22-26.
66. WHO Weekly Epidemiological Record 1997, 72:141-148.
67. CPMP Position Statement on DNA, CPMP/BWP/382/97, EMEA.
68. Griffiths E. Biologicals 1997, 25:359-362.
69. Norling L., Lute S., Emery R., Khuu W., Voisard M., Xu Y., Chen Q., Blank G., Brorson K. Impact of multiple re-use of anion-exchange chromatography media on virus removal. J. Chromategr. A 2005, 79-89.
70. Joint Meeting of the TSE and Vaccine and Related Biological Products Advisory committee http://www.fda.gov/cber/advisory/tse/tsesum072700.htm.
71. CPMP/CVMP, Position Paper, Sept 02 (EMEA/22314/02).
72. U.S. FDA, CBER, Estimating risks for vCJD in vaccines using bovine-derived materials http://www.fda.gov/cber/bse/risk.htm.
73. Burdick M.D., Pifat D.Y., Petteway S.R., Cai K. Clearance of prions during plasma protein manufacture. Transfus. Med. Rev. 2006, 20:57-62.
74. Slaff G. Application of technology platforms to the purification of monoclonal antibodies. BioProcess International Conference April 12-13, 2005.
75. Hatti-Kaul R., Mattiasson B. Release of protein from biological host. Isolation and Purification of Proteins 2003, 1-27. Marcel Dekker, Inc., New York. R. Hatti-Kaul, B. Mattiasson (Eds.).
76. van Hee P., Middelberg A.P.J., van der Lans R.G.J.M., van der Wielen L.A.M. Relation between cell disruption conditions, cell debris particle size, and inclusion body release. Biotechnol. Bioeng. 2004, 88(1):100-110.
77. Wang A., Lewus R., Rathore A.S. Comparison of different options for harvest of a therapeutic protein product from high cell density yeast fermentation broth. Biotechnol. Bioeng. 2006, 94(1):91-104.
78. Axelsson H. Cell separation, centrifugation. The Encyclopedia of Bioprocess Technology: Fermentation, Biocatalysis, and Bioseparation 1999, Wiley, New York, NY. M.C. Flickinger, S.W. Drew (Eds.).
79. Shpritzer R. Evaluation of a continuous disc stack centrifuge for clarification of mammalian cell cultures, Presented at 225th ACS National Meeting, New Orleans, 24 March 2003 American Chemical Society, Washington DC. www.chemistry.org.
80. Lander R., Daniels C., Meacle F. Efficient, scalable clarification of diverse bioprocess streams. Bioprocess Intnatl. 2005, 3(10):32-40.
81. Rechtsteiner H., Kemp ken R., Becker V., Erdmann C., Cole S. Cell separation from mammalian suspension cultures. Bioprocess Intnatl. 2004, 2(1):60-62.
82. Arnold T.E. Fluid purification using charge-modified depth filtration media. BioProcess Intnatl. 2005, 3(10):44-49.
83. Changier M.A., Zydney A.L. Clarification of yeast cell suspensions by depth filtration. Biotechnol. Prog. 2005, 21(5):1552-1557.
84. Maiorella B., Dorin G., Carion A., Harano D. Crossflow microfiltration of animal cells. Biotechnol. Bioeng. 1990, 37:121-126.
85. Sellick I. Improve product recovery during cell harvesting. BioProcess Intnatl. 2003, 1(4):62-65.
86. Lasky M., Grant D. Use of microporous hollow fiber membranes in cell harvesting. Am. Biotechnol. Lab. 1985, 3(6):16-21.
87. Wang A., Lewus R., Rathore A.S. Comparison of different options for harvest of a therapeutic protein product from high cell density yeast fermentation broth. Biotechnol. Bioeng. 2006, 94(1):91-94.
88. Mattiasson B., Nandakumar M.P. Physiochemical basis of expanded bed adsorption for protein purification. Separation Science and Technology 2000, Vol. 2:417-430. Academic Press, London.
89. Beck J.T., Williamson B., Tipton B. Direct coupling of expanded bed adsorption with a downstream purification step. Bioseparation 1999, 8:201-207.
90. Knoblechner J.M. Interfacing Pichia pastoris cultivation with expanded bed adsorption. Biotechnol. Bioeng. 2006, 93(6):1040-1049.
91. Kawasaki T. Biopharma in Japan, Pharma Focus Asia 2006, 1:29-34.
92. Schmidt S. Large-Scale Crystallization for Downstream Processing of Proteins. Oral Presentation. BioProcess International European Conference 12 April 2005.
93. DePalma A. Providing value in downstream operations. GEN 2005, 25(18):50-53.
94. DePalma A. Cost-driven chromatography. Pharm. Manuf. 2005, 4(10):30-38.
95. Svensson J. Development of a multivariate statistical model for accurate scale-up predictions of pressure/flow properties. Oral presentation ACS National Meeting 2005.
96. Gagnon P., Grund E. Large-scale process development for hydrophobic interaction chromatography. Part III. Factors affecting capacity determination. BioPharm 1996, 9:34-39.
97. Yamamoto S., Nakanishi K., Matsuno R. Ion-Exchange Chromatography of Proteins. Chromatographic Science Series 1988, Vol. 43:258. Marcel Dekker, New York, Chapter 8.
98. Janson J.-C., Hedman P. On the optimization of process chromatography of proteins. Biotechnol. Progr. 1987, 3:9-13.
99. Lindqvist B., Storgårds T. Molecular-sieving properties of starch. Nature (London) 1955, 175:511-512.
100. Lathe G.H., Ruthven C.R.J. The separation of substances and estimation of their relative molecular sizes by use of columns of starch in water. Biochem. J. 1956, 62:665-674.
101. Porath J., Flodin P. Gel filtration. A method for desalting and group separation. Nature 1959, 183:1657-1659.
102. Hagel L. Pore size distributions. Aqueous Size-Exclusion Chromatography 1988, 119-155. Elsevier, Amsterdam. P.L. Dubin (Ed.).
103. Hagel L., östberg M., Andersson T. Apparent pore size distributions of chromatography media. J. Chromatogr. A 1996, 743:33-42.
104. Hagel L. Gel filtration. Protein Purification, Principles, High Resolution Methods, and Applications 1989, 63-106. VCH, New York. J.-C. Janson, L. Rydén (Eds.).
105. Hagel L., Lundström H., Andersson T., Lindblom H. Properties, in theory and practice, of novel gel filtration media for standard liquid chromatography. J. Chromatogr. 1989, 476:329-344.
106. Hagel L., Andersson T. Characteristics of a new agarose medium for high-performance gel filtration chromatography. J. Chromatogr. 1984, 285:295-306.
107. Hagel L., Janson J.-C. Size-exclusion chromatography. Chromatography 1992, A267-A307. Elsevier, Amsterdam. 5th edn. E. Heftmann (Ed.).
108. Hagel L. Desalting and buffer exchange with Sephadex G-25. Application Note 18-1127-73 1998, Amersham Pharmacia Biotech, Uppsala.
109. Protein Purification, Principles, High Resolution Methods, and Applications 1989, VCH, New York. J.-C. Janson, L. Rydén (Eds.).
110. Sofer G.K., Nyström L.-E. Process Chromatography 1989, A Practical Guide, Academic Press, London.
111. Lacki K. Where will further improvements in chromatography come from?. MBI lecture at UCL February 1st, 2007, London.
112. Carr P.W., Tan L.C., Park J.H. Revisionist look at solvophobic driving forces in reversed-phase liquid chromatography. Comparison of the behaviour of nonpolar and polar solutes. J. Chromatogr. A 1996, 724:1-12.
113. Hearn M.T.W. High resolution reversed phase chromatography. Protein Purification, Principles, High Resolution Methods, and Applications 1989, 175-206. VCH, New York. J.-C. Janson, L. Rydén (Eds.).
114. Hancock W.S., Bishop C.A., Prestidge R.L., Harding D.R.K., Hearn M.T.W. High-pressure liquid chromatography of peptides and proteins. II. The use of phosphoric acid in the analysis of underivatised peptides by reversed-phase high-pressure liquid chromatography. J. Chromatogr. 1978, 153:391-398.
115. Olson C.V., Reifsnyder D.H., Canova-Davis E., Ling V.T., Builder S.E. Preparative isolation of recombinant human insulin-like growth factor by reversed-phase high-performance liquid chromatography. J. Chromatogr. 1994, 675:101-112.
116. Snyder L.R. Cited in: Weiss, M.D. Rules and issues changes as chromatographic purifications go scale-up. Gene. Eng. News August, 7 1989.
117. Pearson J.D., Lin N.T., Regnier F.E. The importance of silica type for reverse-phase protein separations. J. Chromatogr. 1982, 124:217-230.
118. Karlson J.R., Renlund S. Rapid and systematic development of methods for preparative purification of synthetic peptides. Prep. 1996, Washington, DC May 20-22, 1996, Presentation.
119. Boerner R., Clouse K. Defining your product profile and maintaining control over it, Part 3. Bio. Process. Int. 2005, 3(9):50-56.
120. Bio. Quality. 2006, 11(3):2.
121. Klein M.L. HPLC and mass spectrometry approaches to protein and carbohydrate characterization. Am. Pharm. Rev. 2005, 8(5):108-113.
122. Brorson K., Phillips J. Defining your product profile and maintaining control over it, Part 4. BioProcess. Int. 2005, 3(10):50-54.
123. Cromwell M. Protein aggregation and biopharmaceutical development. AAPS Newsmagazine 2006, 9(6):14-17.
124. Slaff G. Application of technology platforms to the purification of monoclonal antibodies. BioProcess International Conference April 12-13, 2005.
125. Lowery S. Designing a contamination control program. Microbiology in Pharmaceutical Manufacturing 2001, PDA/DHI, Bethesda, MD. R. Prince (Ed.).
126. Bill E., Lutz U., Karlsson B.M., Sparrman M., Allgaeir H. Optimization of protein G chromatography for biopharmaceutical monoclonal antibodies. J. Mol. Recognit. 1995, 8:90-94.
127. Chang A. FDA Regulator's Experience January 2002, WCBP, Washington, DC, Oral Prentation.
128. Morrow K.J. Large-scale production of antibodies. GEN 2006, 26(4):34-37.
129. Chiarello-Ebner K. Pursuing efficiency: new developments in cleaning technology. Pharm. Technol. 2006, 30(3):52-64.
130. Sherwood D. Cleaning multiuse facility issues. Biopharmaceutical Process Validation 2000, 235-249. Marcel Dekker, New York. G. Sofer, D.W. Zabriskie (Eds.).
131. Cleaning and Cleaning Validation: A Biotechnology Perspective, PDA 1996, PDA, Bethesda, MD.
132. Scott D.E., Asher D.M. Transmissible spongiform encephalopathies: decontamination considerations for manufacturing environments. Am. Pharm. Rev. 2006, 9(3):34-38.
133. Foster P.R., Griffen B.D., Bienek C., Mcintosh R.V., Gregor I.R., Somerville R.A., Steele P.J., Reichl H.E. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII. Vox Sang 2004, 86:92-99.
134. Martinez J.E. Mode of action and development of resistance to disinfectants, part 1. BioProcess Intnatl. 2005, 3(8):32-38.
135. Wistreich G.A., Lechtman M.D. Microbiology 1980, Glencoe, London. 3rd edn.
136. Korczynski M.S. International Standards Organization Technical Committee 198 Worldwide Standards for Sterilization. PDA Letter 1990, XXVI:4.
137. Inspection of Biotechnology Manufacturers, P1024-1 December 2005, PIC/S.
138. Technical Report No. 42, Process Validation of Protein Manufacturing. PDA J. Pharm. Sei. Technol. 2005, 59(S-4). PDA, PDA, Bethesda MD.
139. Moldenhauer J. Rapid microbiological methods and the PAT initiative. BioPharm. Int. 2005, 18(12):31-46.
140. Lagerlof A. Inactivation of microbiological contamination in MabSelect SuRe by NaOH. Amersham Biosciences, Internal Technical Report 2004.
141. Bioburden recovery validation task force. Technical report: bioburden recovery validation. J. Parenteral Sei. Technol. 1990, 44:324-331. PDA.
142. Rathore A.S., Sofer G. Life span studies for chromatography and filtration media. Process Validation in Manufacturing of Biopharmaceuticals 2005, 169-203. Marcel Dekker, New York. A.S. Rathore, G. Sofer (Eds.).
143. Campbell J. Validation of a filtration step. Process Validation in Manufacturing of Biopharmaceuticals 2005, 205-275. Marcel Dekker, New York. A.S. Rathore, G. Sofer (Eds.).
144. US FDA, 21 CFR Part 211.67.
145. Winter B., Contino A., O'Neill G. Chlorine dioxide, part 1. BioProcess Intnatl. 2005, 3(11):42-48.
146. Tidswell E.C. Bacterial adhesion: considerations within a risk-based approach to cleaning validation. PDA J. Pharmaceutical Sei. Technol. 2005, 59:10-32.
147. Riedewald F. Bacterial adhesion to surfaces: the influence of surface roughness. PDA J. Pharm. Sei. Technol. 2006, 60(3):164-171.
148. Sanitization of AKTApilot with sodium hydroxide. Application Note, 18-1171-11 AA, 2003-05, GE Healthcare, Uppsala Sweden.
149. Agalloco J. Validation: an unconventional review and reinvention. PDA J. Phann. Sci. Technol. 1995, 49(4):175-179.
150. Brewster K. President Yale University, Speech Dec. 13, 1977.
151. Process validation of protein manufacturing. PDA J. Pharm. Sci. Technol. 2005, 59(Supplement V). PDA Technical Report No. 42, No. S-4.
152. Good Manufacturing Practice Guide for Active Phannaceutical Ingredients ICH Q7A, Available from. http://www.ich.org.
153. Wrench N. English journalist and commentator, Belfastman. From The Manager's Book of Quotations, LD Eigen and JP Siegel 1989, American Management Association, Rockville, MD.
154. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use Feb 1997, U.S. FDA, CBER.
155. Good Manufacturing Practices Annex 13 Manufacture of Investigational Medicinal Products July 2003, Vol. 4. European Commission.
156. Draft Guidance for Industry: INDs-Approaches to Complying with CGMP During Phase I January 2006, U.S. FDA.
157. Guidance for Industry, Investigators, and Reviewers-Exploratory IND Studies January 2006, U.S. FDA.
158. EMEA, CHMP Concept Paper on the Development of a Guideline on Viral Safety Evaluation of Biotechnology Products to be used in Clinical Trials. EMEA/CHMP/BWP/ 124447/2004.
159. Note for Guidance on Plasma-Derived Medicinal Products, January 2001, CPMP/BWPP/269/ 95/rev.3 available from, available from. http://www.emea.eu.int/.
160. Ritter N. What is Test Method Qualification?. Proceedings of the WCBP Strategy Forum 24 July 2003.
161. Simek S.L. Characterization of gene therapy products and the impact of manufacturing changes on product comparability. State of the Art Analytical Methods for the Characterization of Biological Products and Assessment of Comparability 2005, V 122:139-144. Dev. Biol. Karger, Basel.
162. Roscioli N., Vargo S. Facility design issues-a regulatory perspective. Process Validation in Manufacturing of Biopharmaceuticals 2005, 327-394. CRC Press, Boca Raton, FL. A.S. Rathore, G. Sofer (Eds.).
163. EMEA, Note for Guidance on TSEs, Feb 2001, EMEA/410/10-Final.
164. Pharmaceutical Inspection Convention/Pharmaceutical Inspection Co-operation Scheme (PIC/S), Aide-Memoires: Inspection of Biotechnology Manufacturers, PI 024-1 Available from. http://www.picscheme.org.
165. Guidance for Industry: Monoclonal Antibodies Used as Reagents in Drug Manufacturing March 2001, U.S. FDA.
166. Bader F. Immunogenicity of Therapeutic Proteins: A Case Report. Oral Presentation. Scientific Considerations Related to Developing Follow-On Protein Products, FDA Public Workshop September 2004, Washington, DC.
167. Boven K., Knight J., Bader F., Russert J., Eckhardt K.U., Casadevall N. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol. Dial. Transplant. 2005, 20(Suppl 3):33-40.
168. Roth G.Y. Extractables and leachables: regulatory pressures fuel methods development. Contract Pharma 2005, 7(3):40-44.
169. Bennan J., Miller D., Seely B., Bing F., Fernandez J., van Deinse H. Evaluation of extractables from product-contact surfaces. BioPharm Int. 2002, 15(12):22-33.
170. Jenke D. Extractable/leachable substances from plastic materials used as phann aceutical product containers/devices. PDA J. Phann. Sci. Technol. 2002, 56(6):332-371.
171. Farid S.S., et al. Decision-support tool for assessing biomanufacturing strategies under uncertainty: stainless steel versus disposable equipment for clinical trial material preparation. Biotechnol. Prog. 2005, 21:486-497.
172. Standard E2500-07, Standard Guide for Specification, Design and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment ASTM. http://www.astm.org.
173. Unknown consultant.
174. Final Guidance for Industry and FDA Stalt January 2002, U.S. FDA.
175. U.S. FDA, Warning Letters can be found at. http://www.fda.gov/foi/warning.htm.
176. GAMP Guide for Validation of Automated Systems, ISPE ISPE, Available from. http://www.ispe.org.
177. U.S. FDA, Title 21, U.S. Code of Federal Regulations (CFR), Part 11, Electronic Records and Electronic Signatures.
178. Moscariello J., Lightfoot E., Rathore A. Efficiency measurements for chromatography columns. Biophann. Int. 2005, 18(8):58-64.
179. and www.emea.eu.int/inspections/PAThome.html. http://www.fda.gove/cder/OPS/PAT.htm.
180. Webber K. AAPS, Oral Presentation 2004.
181. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing U.S. FDA, Available at. http://www.fda.gov/cber/gdlns/.
182. Moldenhauer J. Rapid microbiological methods and the PAT initiative. BioPhann. Int. 2005, 18(12):31-46.
183. Lasch J., Janowski F. Leakage stability of ligand-support conjugates under operational conditions. Enzyme Microb. Technol. 1998, 10:312-314.
184. Franklin J.N. Fragments of Protein A Eluted During Protein A Affinity Chromatography, Oral Presentation, Abstract BIOT337. 232nd ACS National Meeting September 10-14, 2006.
185. Farid S.S. Process economics of industrial monoclonal antibody manufacture. J. Chromatogr. B 2006, :10.1016/j.jchromb.2006.07.037.
186. Werner R.G. Arzneim.Forsch./Drug Res. 1998, 48:523.
187. Coopers, Lybrand Pharmaceuticals: Creating Value by Transforming the Cost Base-Our Approach 1997.
188. Rosenberg M. Proceedings of IBC's Production and Economics of Biopharmaceuticals-Transcending the Limits of Manufacturing Medicines November 13-15, 2000.
189. Kelley B.D. Curr. Opin. Biotechnol. 2001, 12(2):173.
190. Mullen J. Proceedings of IBC's Production and Economics of Biopharmaceuticals-Transcending the Limits of Manufacturing Medicines November 13-15, 2000.
191. Chadd H.E., Chamow S.C. Curr. Opin. Biotechnol. 2001, 12:188.
192. Werner R.G. J. Biotechnol. 2004, 113(1-3):171.
193. Myers J. Economic Considerations in the Development of Downstream Steps for Large-Scale Commercial Biopharmaceutical Processes. Presented at IBC Production and Economics of Biopharmaceuticals November 13-15, 2000.
194. Nachtmann F. Single-Use Disposables, Benefits and Limitations in Process Development and Manufacturing. Presented at IBC BioProcess International Conference April 2005.
195. Walsh C. Key Management Ratios, How to Analyze, Compare, and Control the Figures That Drive Company Value 1996, Pitman Publishing, London.
196. Amgen Annual Report available at. http://www.gene.com.
197. Genentech Annual Report available at. http://www.gene.com.
198. Serono Annual Report available at. http://www.serono.com.
199. Medlmmune Annual Report available at. http://www.medimmune.com.
200. Beschluss des Gemeinsamen Bundesausschusses über eine änderung der Arzneimittelrichtlinie/ AMR am 18. Juli 2006, Anlage 1 zum RS 218/2006 July 25, 2006.
201. Wolk B., Bezy P., Arnold R., Blank G. Characteristics of a Good Antibody Manufacturing Process, Bioprocess International September 2003, 50-58.
202. Genentech web publication on manufacturing facilities, available at Genetic Engineering News. http://www.gene.com.
203. Kelley B. Designing a 10-ton Mab Process: Is Conventional Chromatography Limiting?. Presented at American Chemical Society, Annual Conference, BIOT Division September 2006.
204. Adamson B. A New Era in Biotechnology. Presented at IBC Bioproduction 2006 October 2006.
205. Defense Advanced Research Projects Agency (DARPA), BAA 06-31, Accelerated Manufacturing of Pharmaceuticals (AMP), Published by US Government Federal Business Opportunities http://www.fbo.gov/spg/ODA/DARPA/CMO/BAA06-31/Attachments.html.
206. Sommerfeld S., Strube J. Challenges in biotechnology production-generic processes and process optimization for monoclonal antibodies. Chem. Eng. Process. 2005, 44:1123-1137.
207. Ambrosius D. Assessment of Purification Technologies. Presented at IBC Bioprocess International Conference May 2005.
208. Zhou J.X., Tressel T. Basic Concepts in Q Membrane Chromatography for Large-Scale Antibody Production April 3, 2006, American Chemical Society and American Institute of Chemical Engineers, Published on Web.
209. Gottschalk U., Fischer-Fruehholz S., Reif O. Membrane adsorbers, a cutting edge process technology at the threshold. Bioprocess Int. 2004, 2(5):56-65.
210. Walter J.K. Strategies and considerations for advanced economy in downstream processing of biopharmaceutical proteins. Bioseparation and Bioprocessing 1998, Vol. 2:447-460. Wiley VCH, New York, N.Y. G. Subramanian (Ed.).
211. Johansson H.J. Current and Future Advances in Development of Downstream Processes for Purification of Monoclonal Antibodies. Presented at IBC Bioprocess International Conference November, 2006.
212. Lewis-Sandy D. Optimizing Consumables Reuse for Commercial Therapeutic Production. Presented at IBC Bioprocessing 2002.
213. Womack J.P., Jones D.T. LEAN Thinking: Banish Waste and Create Wealth in Your Corporation 1996, Simon & Schuster, London. 1st edn.
214. Intelligen, SuperPro Designer software information available from. http://www.intelligen.com.
215. Werner R.G. New frontiers in bio processing-what does the future hold?. Presented at 5th Annual Biological Production Forum April 2006.
216. Levine H.L. Assessing Strategic Options for Biologies Manufacturing. Presented at IBC Bioprocess International Conference October 2004.
217. McDaniel A. Implementation of a Rapid System for Microbial Detection in Mammalian Cell Culture at Wyeth Biopharma. Presented at IBC Process Analytical Technologies for Biologics 2005 June, 2005.
218. Kamarck M.E. Building Biomanufacturing Capacity-the Chapter and the Verse. Nat. Biotechnol. 2006, 24(5):503-505.
219. Turner B.G. Approaches to Achieving 5 g/L Antibody Titers Through Process Development. Presented at Bioprocess International Conference November, 2006.
220. Datar R., Rosén C.-G. Downstream Process Economics. Separation Processes in Biotechnology 1990, 741-793. Marcel Dekker, New York and Basel. J.A. Asenjo (Ed.).
221. Vunnum S., et al. Anion Exchange Purification of Mabs: Weak Partitioning Chromatography. Presented at ACS, BIOT Division September, 2006.
222. Francis R., Bonnerjea J., Hill C.R. Validation of the Re-use of Protein A Sepharose for the Purification of Monoclonal Antibodies. Presented at the Second International Symposium on 'Separations for Biotechnology' 1990, Elsevier Applied Science, London & New York, Published in 'Separations for Biotechnology 2'. D.L. Pyle (Ed.).
223. Breece T., Silapie J., Bergenstrahle A., Johansson H.J., Schmelzer Ch. Characterization and Optimization of Direct Capture of Monoclonal Antibodies on MabSelect?. Presented at GAb 2002, International Symposium on Downstream Processing of Genetically Engineered Antibodies and Related Molecules October, 2002.
224. Turner B.G. Comparison of Technology Platforms for Antibody Manufacturing: The Abbott Perspective. Presented at BIO 2005.
225. Bezy P. Efficient Pilot Plant Utilization. Presented at IBC BioProcess International Conference April, 2005.
226. Jagschies G., Grönberg A., Björkman T., Lacki K., Johansson H.J. Technical and Economical Evaluation of Downstream Processing Options for Monoclonal Antibody (MAb) Production, Supplement to Biopharm International June, 2006.
227. Creighton T.E. Proteins, Structures and Molecular Properties 1993, W. H. Freeman and Company, New York.
228. Branden C., Tooze J. Introduction to Protein Structure 1991, Garland Publishing Inc., New York.
229. Mant C.T., Zhou N.E., Hodges R.S. Amino acids and peptides. Chromatography 1992, B137. Elsevier, Amsterdam. 5th edn. E. Heftmann (Ed.).
230. Lupas A. Coiled coils: new structures and new functions. TIBS 1996, 2:375-382.
231. Aguilar M.-I., Richards K.L., Round A.J., Hearn M.T.W. Molecular definition of the retention parameters of peptides separated by RP-HPLC. Peptide Res. 1994, 7:207-217.
232. Borman S. Biochemical applications of mass spectrometry take flight. Chem. Eng. News. 1995, 25:23-32.
233. Aguilar M.-I., Hearn M.T. Peptides. Encyclopedia of Analytical Science 1995, 3763-3769. Academic Press, London.
234. Wrigley C.W. Giant proteins with flour power. Nature 1996, 381:738-739.
235. Werner M.H., Clore G.M., Gronenborn A.M., Kondoh A., Fisher R.J. Refolding proteins by gel filtration chromatography. FEBS Lett. 1994, 345:125-130.
236. T. Yang, E. Carredano, W.K. Chung, G. Malmquist and S.M. Cramer, Multi Scale Models for the Prediction of Preparative Protein Ion Exchange Chromatographic Behavior, in preparation.
237. Ståhlberg J., Jö B., Horvath C. Theory for electrostatic interaction chromatography of proteins. Anal. Chem. 1991, 63:1867-1874.
238. Stafström N., Malmquist G. Deviations in pH during gradient elution in ion-exchange chromatography. Presented at HPLC 1996 June 16-21, 1996, San Francisco, CA, U.S.A.
239. Ettre L.S. Nomenclature for Chromatography IUPAC Recommendations 1993. Pure Appl. Chem. 1993, 65:819-872.
240. Karger B.L., Snyder L.R., Horvath C. An Introduction to Separation Science 1973, Wiley, New York.
241. Jandera P., Chuáracek J. Gradient elution in column liquid chromatography, theory and practice. J. Chromatogr. Lib. 1985, 31. Elsevier, Amsterdam.
242. Deemter J.J.V., Zuiderweg F.J., Klinkenberg A. Longitudinal diffusion and resistance to mass transfer as causes of nonideality in chromatography. Chem. Eng. Sci. 1956, 5:271-289.
243. Giddings J.C. Theory of chromatography. Chromatography: a Laboratory Handbook of Chromatographic and Elecrophoretic Methods, Chapter 3 1975, 27-45. Van Nostrand Reinhold Company, New York. E. Heftmann (Ed.).
244. Hagel L. Gel filtration chromatography. Protein Purification, Principles, High Resolution Methods, and Applications 1998, 79-143. Wiley-Liss, New York. 2nd edn. J.-C. Janson, L. Rydén (Eds.).
245. Hagel L., Lundstrom H., Andersson T., Lindblom H. Properties, in theory and practice of novel gel filtration media for standard liquid chromatography. J. Chromatogr. 1989, 476:329-344.
246. Yamamoto S., Nakanishi K., Matsuno R. Ion-Exchange Chromatography of Proteins 1988, 258. Marcel Dekker, Inc., New York.
247. Bristow P.A. Liquid Chromatography in Practice 1976, HETP, Wilmslow, England.
248. Li Q., Grandmaison E.W., Hsu C.C., Taylor D., Goosen M.F.A. Interparticle and intra- particle mass transfer in chromatographic separation. Bioseparation 1995, 5:189-202.
249. Allen T. Particle Size Measurement 1981, 432-436. Chapman and Hall, London.
250. Carman P.C. Determination of the specific surface of powders. J. Soc. Chem. Ind. (Trans.) 1938, 57:225-234.
251. Squire P.G., Magnus A., Himmel M.E. Size exclusion at the external surfaces of spherical packings used in high-performance liquid chromatography. J. Chromatogr. 1982, 242:255-266.
252. Giddings J.C., Kucera E., Russel C.P., Myers M.N. Statistical theory for the equilibrium distribution of rigid molecules in inert porous networks: exclusion chromatography. J. Phys. Chem. 1968, 72:4397-4408.
253. Knox J.H., Scott H.P. Theoretical models for size-exclusion chromatography and calculation of pore size distribution from size-exclusion chromatography data. J. Chromatogr. 1984, 316:311-332.
254. Hagel L., östberg M., Andersson T. Apparent pore size distributions of chromatography media. J. Chromatogr. A. 1996, 743:33-42.
255. Dawkins J.V. Size exclusion chromatography. Polymer Characterisation, Chapter 12 1989, 231-258. Pergamon Press, Oxford. C. Booth, C. Price (Eds.).
256. Hagel L. Effect of sample volume on peak width in high-performance gel filtration chromatography. J. Chromatogr. 1985, 324:422-427.
257. Hagel L. Characteristics of modern media for aqueous size exclusion chromatography. Strategies in Size Exclusion Chromatography, Chapter 13 1996, 225-248. American Chemical Society, Washington, DC, ACS Symposium Series 635. M. Potschka, P. Dubin (Eds.).
258. Chang S.H., Gooding K.M., Regnier F.E. High-performance liquid chromatography of proteins. J. Chromatogr. 1976, 125:103-114.
259. Fernandez E.J., Norton T.T., Jung W.C., Tsavalas J.G. A column design for reducing viscous fingering in size exclusion chromatography. Biotechnol. Progr. 1996, 12:480-487.
260. Fernandez E.J., Grotegut C.A., Braun G.W., Kirschner K.J., Staudaher J.R., Dickson M.L., Fernandez V.L. The effects of permeability heterogeneity on miscible viscous fingering: a three-dimensional magnetic resonance imaging analysis. Phys. Fluids 1995, 7:468-477.
261. Boardman N.K., Partridge S.M. Separations of neutral proteins on ion-exchange resins. Biochem. J. 1955, 59:543-552.
262. Kopaciewicz W., Rounds M.A., Fausnaugh J., Regnier F.E. Retention model for high-performance ionexchange chromatography. J. Chromatogr. 1983, 266:3-21.
263. Ståhlberg J., Jönsson B., Horváth C. Theory for electrostatic interaction chromatography of proteins. Anal. Chem. 1991, 63:1867.
264. Cai C.-H., Romano V.A., Dubin P.L. Ionic strength dependence of protein retention on Superose 12 in SEC-IEC mixed mode chromatography. J. Chromatogr. 1995, 693:251-261.
265. Gallant S.R., Kundu A., Cramer S.M. Modeling non-linear elution of proteins in ion-exchange chromatography. J. Chromatogr. 1995, 702:125-142.
266. Gadam S.D., Jayaraman G., Cramer S.M. Characterization of non-linear adsorption properties of dextran-based poly electrolyte displacers in ion-exchange systems. J. Chromatogr. 1993, 630:37-52.
267. Yamamoto S., Nomura M., Sano Y. Resolution of proteins in linear gradient elution ion exchange and hydrophobic interaction chromatography. J. Chromatogr. 1987, 409:101-110.
268. Malmquist G., Lundell N. Characterization of the influence of displacing salt on the retention in gradient elution ion-exchange chromatography of proteins and peptides. J. Chromatogr. 1992, 627:107-124.
269. Ekström B., Jacobson G. Differences in retention behavior between small and large molecules in ion-exchange chromatography and reversed-phase chromatography. Anal. Biochem. 1984, 142:134-139.
270. Sofer G.K., Nyström L.-E. Process Chromatography, A Practical Guide 1989, Academic Press, London.
271. Yaraaraoto S. Plate height determination for gradient elution chromatography of proteins. Biotechnol. Bioeng. 1995, 48:444-451.
272. Guttman C.M., DiMario E.A. Separation by flow. II application to gel permeation chromatography. Macromolecules 1970, 3:681-691.
273. Komiyama H., Hakuai I. Effects of intraparticle flow on catalytic reactions. J. Chem. Eng. Jpn. 1974, 7:281-286.
274. Rodrigues A.E., Ahn B.J., Zoulalian A. Intraparticle-forced convection effect in catalyst diffusivity measurement and reactor design. AIChE J. 1982, 28:541-546.
275. Regnier F.E. Macroporous divinyl benzene-based media for protein separations, presented at HPLC 1988 22/623/6, 1988.
276. Afeyan N.B., Gordon N.F., Mazsaroff I., Varady L., Fulton S.P., Yang Y.B., Regnier F.E. Flow-through particles for the high-performance liquid chromatographic separation of bio-molecules: perfusion chromatography. J. Chromatogr. 1990, 519:1-29.
277. Gustavsson P.-E., Larsson P.-O. Superporous agarose, a new material for chromatography. J. Chromatogr. A. 1996, 734:231-240.
278. Heeter G.A., Liapis A.I. Perfusion chromatography: performance of periodic countercur-rent column operation and its comparison with fixed-bed operation. J. Chromatogr. A. 1995, 711:3-21.
279. Heeter G.A., Liapis A.I. Effects of structural and kinetic parameters on the performance of chromatographic columns packed with perfusive and purely diffusive adsorbent particles. J. Chromatogr. A. 1996, 743:3-14.
280. Weaver L.E., Carta G. Protein adsorption on cation exchangers: comparison of macroporous and gel-composite media. Biotechnol. Progr. 1996, 12:342-355.
281. Knox J.H., Pyper H.M. Framework for maximizing throughput in preparative liquid chromatography. J. Chromatogr. 1986, 363:1-30.
282. Malmquist G., Brekkan E., Axén A., Ihre H. Dextran modified ion exchange resins-a study of the effect of different loading conditions on the dynamic protein binding capacities. PREP 2006, Baltimore, USA 2006, oral presentation at.
283. Dorsey J.G., Cooper W.T. Retention mechanisms of bonded-phase liquid chromatography. Anal. Chem. 1994, 77:857A-867A.
284. Horváth C., Melander W. Liquid chromatography with hydrocarbanaceous bonded phases; theory and practice of reversed phase chromatography. J. Chromatogr. Sci. 1977, 15:393-404.
285. Carr P.W., Tan L.C., Park J.H. Revisionist look at solvophobic driving forces in reversed-phase liquid chromatography. Ill Comparison of the behavior of nonpolar and polar solutes. J. Chromatogr. 1996, 724:1-12.
286. Koyama J., Nomura J., Shiojima Y., Ohtsu Y., Horii I. Effect of column length and elution mechanism on the separation of proteins by reversed-phase high-performance liquid chromatography. J. Chromatogr. 1992, 625:217-222.
287. Snyder L.R., Stadalius M.A. High performance liquid chromatography separations of large molecules: A general model in High performance liquid chromatography 1986, 265. Academic Press, New York. C. Horvath (Ed.).
288. Mant C.T., Zhou N.E., Hodges R.S. Amino acids and peptides. Chromatography 1992, B137. Elsevier, Amsterdam. 5th edn. E. Heftmann (Ed.).
289. Sadek P.C., Carr P.W., Bowers L.D., Haddad L.C. A radiochemical study of irreversible adsorption of proteins on reversed-phase chromatographic packing materials. Anal. Biochem. 1986, 153:359-371.
290. Katzenstein G.A., Vrona S.A., Wechsler R.J., Steadman B.L., Lewis R.V., Middaugh C.R. Role of conformational changes in the elution of proteins from reversed-phase HPLC columns. Proc. Natl. Acad. Sci. USA 1986, 83:4268-4272.
291. Turula V.E., Haseth J.A.D. Particle beam LC/FT-IR spectrometry studies of biopolymer conformations in reversed-phase HPLC separations: native globular proteins. Anal. Chem. 1996, 68:629-638.
292. Pearson J.D., Lin N.T., Regnier F.E. The importance of silica type for reversed-phase protein separations. Anal. Biochem. 1982, 124:217-230.
293. Engelhardt H., Müller H. Optimal conditions for the reversed-phase chromatography of proteins. Chromatographia 1984, 19:77-84.
294. Kawakatsu M., Kotaniguchi H., Freiser H.H., Gooding K.M. The effects of pore diameter and ligand chain length on fast liquid chromatography of proteins and peptides. J. Liq. Chromatogr. 1995, 18:633-647.
295. Olson C.V., Reifsnyder D.H., Canova-Davis E., Ling V.T., Builder S.E. Preparative isolation of recombinant human insulin-like growth factor by reversed-phase high-performance liquid chromatography. J. Chromatogr. 1994, 675:101-112.
296. Melander W.R., Rassi Z.E., Horváth C. Interplay of hydrophobic and electrostatic interactions in biopolymer chromatography. Effect of salts on the retention of proteins. J. Chromatogr. 1989, 469:3-27.
297. Israelachvili J., Wennerström M. Role of hydration and water structure in biological and colloidal interactions. Nature 1996, 379:219-225.
298. To B.C.S., Lenhoff A.M. Hydrophobic interaction chromatography of proteins II. Solution thermodynamic properties as a determinant of retention. J. Chromatogr. A. 2007, 1141:235-243.
299. Gagnon P., Grund E., Lindbäck T. Large-scale process development for hydrophobic interaction chromatography. Part I. Gel selection and development of binding conditions. BioPharm 1995, 8:21-27.
300. Parsegian V.A. Hopes for Hofmeister. Nature 1996, 378:335-336.
301. Leberman R., Soper A.K. Effect of high salt concentrations on water structure. Nature 1995, 378:364-366.
302. Gagnon P., Grund E. Large-scale process development for hydrophobic interaction chromatography, Part 3. Factors affecting capacity determination. Biopharm 1996, 9:34-39.
303. Gagnon P., Grund E. Large-scale process development for hydrophobic interaction chromatography. Part IV. Controlling selectivity. BioPharm 1996, 9:54-64. 56,58.
304. Eriksson K.-O. Hydrophobic interaction chromatography. Protein Purification, Principles, High Resolution Methods, and Applications 1989, 207-226. VCH Publishers Inc., New York. J.-C. Janson, L. Rydén (Eds.).
305. Gagnon P., Grund E., Lindbäck T. Media selection and rapid development of binding conditions for high-performance, hydrophobic interaction chromatography (HIC). LC-GC Int. 1995, 8:502-510.
306. Kårsnäs P., Lindblom T. Characterization of hydrophobic interaction and hydrophobic interaction chromatography media by multivariate analysis. J. Chromatogr. 1992, 599:131-136.
307. Fausnaugh J.L., Pfannkoch E., Gupta S., Regnier F.E. High-performance hydrophobic interaction chromatography of proteins. Anal. Biochem. 1984, 137:464-472.
308. Tibbs T.L., McNay J.L.M., Sokol J.M., O'Connell J.P., Fernandez E.J. Toward an understanding of conformation in hydrophobic chromatography, P059. presented at ISPPP 2000 November 5-8, 2000.
309. Pendlebury D. The use of disposable systems in the manufacture of biopharmaceuticals. BioProcessing J. 2005, (May/June):59-63.
310. Guidance for industry. INDs-approaches for complying with CGMP during phase I. Draft Guidance January, 2006, U.S. FDA.
311. Farid S.S., Washbrook J., Titchner-Hooker N.J. Decision-support tool for assessing bio-manufacturing strategies under uncertainty: stainless steel versus disposable equipment for clinical trial material preparation. Biotechnol. Prog. 2005, 21:486-497.
312. Williams K.L. Differentiating endotoxin removal from inactivation in vial component depyro- genation validations. Pharm. Technol. 1995, 19(10):72-84.
313. Miller D.H. Quality assurance of production materials for biotechnology. Quality Assurance for Biopharmaceuticals 1994, 61-74. Wiley, New York. J.F. Huxoll (Ed.).
314. Riedewald F. Bacterial adhesion to surfaces: the influence of surface roughness. PDA J. Pharm. Sci. Technol. 2006, 60(3):164-171.
315. Tuthill A.H. Stainless steel: surface cleanliness. Pharm. Eng. 1994, 14(6):34-44.
316. Wang Y.J., Chien Y.W. Sterile Pharmaceutical Packaging Compatibility and Stability. Technical Report No. 5 1984, Parenteral Drug Association, Philadelphia.
317. Cowan C.T., Thomas C.R. Materials of construction in the biological process industry. Process Biochem. 1988, 23(1):5-11.
318. Meyer P. Vessels for biotechnology. Bioprocess Engineering: Systems, Equipment and Facilities 1995, 189-214. Wiley, New York. B.K. Lydersen, N.A. D'Elia, K.L. Nelson (Eds.).
319. Instrumentation for high performance liquid chromatography. J. Chromatogr. Library 1978, 13:43-74. N.A. Paris.
320. McCabe W.L., Smith J.C. Unit Operations of Chemical Engineering 1976, McGraw-Hill, New York.
321. Coulson J.M., Richardson J.F. Chemical Engineering 1983, Vol. 6:150-154. Pergamon Press, New York.
322. Gebauer K.H., Luo X.L., Barton N.G., Stokes A.N. Efficiency of preparative and process column distribution systems. J. Chromatogr. A 2003, 1006:45-60.
323. Section II: Material Specifications. Section VIII: Stainless Steel. Section X: Plastics 1986, Boiler and Pressure Vessel Codes, American Society of Mechanical Engineers, Fairfield, NJ.
324. A.D. Meikblatt. N6: Glass. Nl: Plastic. W2, W4, W7, and B8: Stainless Steel. TUV (Verenigunt der Technischem Uberwachungs Vereine), Essen.
325. Glaser V. Sanitary piping and pump design key to fluid transport in bioprocess facilities. Gen. Eng. News 1995, 15(5):14.
326. Adey H., Pollan M.S. Piping and valves for biotechnology. Bioprocess Engineering: Systems, Equipment and Facilities 1994, 213-252. Wiley Interscience, New York.
327. Allee A. Validation of different positive displacement pumps for sterile processes. Gen. Eng. News 1995, 15(3):13.
328. Stover R. Bioprocess Engineering: Systems, Equipment and Facilities 1994, 253-315. Wiley Interscience, New York.
329. Carson K.L. Trend toward proven industrial process control methods in bioprocessing. Gen. Eng. News 1995, 15(15):8.
330. östergren K. Compaction, Flow and Dispersion in a Chromatographic Column. PhD Thesis 1997, University of Lund.
331. Luo X., Barton N.G., Gebauer K.H., Stokes A.N. Simulation of packed bed formation in chromatography columns. Proceedings of the WCPT World Congress of Particle Technology 2002.
332. Keener R.N., Maneval J.E., Fernandez E.J. Toward a robust model of packing and scale-up for chromatographic beds. 1. Mechanical compression. Biotechnol. Prog. 2004, 20:1146-1158.
333. Yew B.G., Ureta J., Shalliker R.A., Drumm E.C., Guiochon G. Application of the rheology of particulate materials to the study of the properties of column beds. II-Modeling of the stress-strain behavior. AIChE J. 2003, 49:642.
334. Hemph R., Svensson J., van Wachem B., Almstedt A.E. Discrete eluent simulations and experimental validation of particle packing in a 5 mm chromatography column. presented at the International Conference for Multiphase Flow July 9-13, 2007.